Quote Request
Squamous Cell Carcinoma
With extensive expertise in cancer biology, Alfa Cytology aims to advance the understanding of squamous cell carcinoma and the development of targeted therapies through innovative and comprehensive research approaches.
Introduction to Squamous Cell Carcinoma
Squamous cell carcinoma (SCC) is a malignant tumor arising from squamous epithelial cells, which are found in various tissues throughout the body, including the skin, lungs, esophagus, and cervix. SCC is characterized by the abnormal and uncontrolled proliferation of these cells, leading to tumor formation. It is the second most common form of skin cancer, following basal cell carcinoma, but can also occur in other organs. Recently, advancements in genomic and molecular profiling have enhanced the understanding of SCC pathogenesis, paving the way for targeted therapeutic interventions.
Fig. 1 The role of cutaneous squamous cell carcinoma (cSCC) cell-derived EVs on CAF activation in the tumor stroma. (Li C, et al, 2023)
Therapeutics for Squamous Cell Carcinoma
The clinical pipeline for squamous cell carcinoma includes a variety of novel agents designed to enhance therapeutic efficacy and minimize side effects. The following are key examples of drugs currently under investigation, each with unique mechanisms of action and targets.
| Therapeutics | Molecular Type | Target | Phase |
|---|---|---|---|
| Erbitux | Monoclonal Antibody | EGFR | Approved for head and neck SCC, ongoing studies in other SCC types to explore additional indications. |
| Ibrance | Small Molecule Inhibitor | CDK4/6 | Phase II clinical trials for SCC, with a focus on combination therapy with other agents. |
| TSR-042 | Monoclonal Antibody | PD-1 | Phase II clinical trials for various solid tumors, including SCC. |
| Cyramza | Monoclonal Antibody | VEGF receptor-2 | Phase II clinical trials for SCC, particularly in combination with chemotherapy. |
| Gilotrif | Small Molecule Inhibitor | EGFR, HER2, and HER4 | Phase II clinical trials for SCC, especially for patients with EGFR mutations. |
Our Services
With state-of-the-art preclinical research facilities and a team of dedicated biologists and scientists, Alfa Cytology provides cancer mechanism research services, modeling services, drug discovery services, diagnostic development services, and preclinical research services for basic research and innovative therapy development for SCC. We are committed to unraveling the complex mechanisms of SCC and providing a full range of services to scientists exploring innovative therapies around the world.
Basic Research Services for Squamous Cell Carcinoma
- Cell Biology Research Services: Conducts comprehensive studies on cellular behaviors, interactions, and responses to various stimuli in squamous cell carcinoma.
- Molecular Biology Services: Provides detailed analyses of genetic and molecular mechanisms underlying SCC, including gene expression and mutation profiling.
- SCC Progression and Metabolic Analysis: Investigates the metabolic pathways and progression mechanisms of SCC to identify potential therapeutic targets and biomarkers.
Squamous Cell Carcinoma Modeling Services
We provide a comprehensive suite of squamous cell carcinoma modeling services to support preclinical research. These services are designed to replicate the complexity of SCC in various contexts, enabling detailed studies of tumor biology and therapeutic response. The types of SCC modeling services offered include but are not limited to the following:
Utilizing a diverse array of SCC cell lines, we offer high-throughput screening and mechanistic studies. These models are pivotal for understanding cellular responses to different treatments and for identifying potential drug targets.
Three-Dimensional (3D) Culture Models
Advanced 3D culture systems mimic the tumor microenvironment more accurately than traditional 2D cultures. These models provide insights into cell-cell interactions, drug penetration, and resistance mechanisms.
Patient-Derived Xenograft (PDX) Models
By implanting patient SCC tissue into immunocompromised mice, the PDX model maintains the heterogeneity of the original tumor, which can help evaluate the efficacy of novel therapies.
Genetically Engineered Mouse Models (GEMMs)
GEMMs are designed to carry specific genetic mutations found in human SCC, allowing for the study of tumor development and progression in a controlled genetic background.
SCC Diagnostic Development Services
- Blood-based Biomarker Discovery
- Tissue Biomarker Discovery
Imaging Services
- Tumor Area Quantification
- Tissue Imaging and Analysis for Immuno-oncology
- Imaging Services for Tumor Microenvironment
- Genomics
- Transcriptomics
- Proteomics
- Epigenomics
- Immune-omics
- Single-Cell Omics
- Spatial Omics
Alfa Cytology is committed to providing comprehensive solutions for preclinical research and the development of innovative therapies for pancreatic cancer. We provide basic cellular research, genetic/molecular research, diagnostics development, and tumor modeling for different types of pancreatic cancer to meet the full range of customer needs. The types of molecules we can develop involve small-molecule drugs, therapeutic antibodies, peptide drugs, gene therapies, cellular therapies, and more. Our customer service representatives are available 24 hours a day, Monday through Sunday. If interested in our services, please do not hesitate to contact us.
Reference
- Li C, et al. Cutaneous squamous cell carcinoma-derived extracellular vesicles exert an oncogenic role by activating cancer-associated fibroblasts. Cell death discovery. 2023, 9(1): 260.
